LONG MINI FUTURE WARRANT - NOVO-NORDISK B | Market Closed - BOERSE MUENCHEN 02:25:08 2024-05-31 pm EDT | ||
| 209.8 EUR | +1.15% |
|
| 1 month | +3.00% | ||
| 3 months | +15.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 209.8 | +1.15% |
| 24-05-30 | 207.4 | +0.73% |
| 24-05-29 | 205.9 | -0.21% |
| 24-05-28 | 206.4 | -0.81% |
| 24-05-27 | 208 | -1.08% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 02:25 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GF749P |
| ISIN | DE000GF749P8 |
| Date issued | 2020-11-18 |
| Strike | 145.2 kr |
| Maturity | Unlimited |
| Parity | 0.5 : 1 |
| Emission price | 18.71 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 213.4 € |
|---|---|
| Lowest since issue | 43.13 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
